AIM To perform a systematic review and meta-analysis on proton pump inhibitors (PPIs)
therapy and the risk of Clostridium difficile infection (CDI). METHODS We conducted a …

Clostridium difficileinfection (CDI) is a leading cause of hospital-associated gastrointestinal
illness and places a high burden on our health-care system. Patients with CDI typically have …

Abstract Scope In 2009, the European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) published the first treatment guidance document for Clostridioides …

Triptolide (TP), a traditional Chinese medicine, has been reported to be effective in the
treatment of autoimmune diseases and exerting antineoplastic activity in several human …

This document updates and expands the initial Infectious Diseases Society of America
(IDSA) Fever and Neutropenia Guideline that was published in 1997 and first updated in …

Objectives To update the evidence for associations between antibiotic classes and hospital-
acquired Clostridium difficile infection (HA-CDI). Methods Electronic databases of journal …

Abstract Epidemic C. difficile (027/BI/NAP1) has rapidly emerged in the past decade as the
leading cause of antibiotic-associated diarrhea worldwide. However, the key events in …

Since publication of the Society for Healthcare Epidemiology of America position paper on
Clostridium difficile infection in 1995, significant changes have occurred in the epidemiology …

Clostridium difficile epidemiology has changed in recent years, with the emergence of highly
virulent types associated with severe infections, high rates of recurrences and mortality …

OBJECTIVES: Several studies have raised concern regarding the possible association
between proton-pump inhibitors (PPIs) andClostridium difficileinfection (CDI). We aimed to …